Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference

Rhea-AI Summary

Equillium, a clinical-stage biotechnology company, announced that its CEO Bruce Steel will present at the H.C. Wainwright Virtual BioConnect Conference on January 11, 2021, at 6:00 am EST. This presentation will focus on itolizumab, a treatment for severe autoimmune and inflammatory disorders. A webcast of the presentation will be accessible on the company’s website under the “Investors” section for 30 days following the event.

Equillium is dedicated to addressing high unmet medical needs in severe immuno-inflammatory diseases.

LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on January 11, 2021 at 6:00 am EST.

A webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/ for 30 days.

About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.
For more information, visit www.equilliumbio.com.

Investor Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
+1-619-302-4431
ir@equilliumbio.com

Media Contact
Katherine Carlyle Smith
Senior Account Associate
Canale Communications
+1-805-907-2497
katherine.smith@canalecomm.com

FAQ

When will Equillium's CEO present at the H.C. Wainwright Virtual BioConnect Conference?

Equillium's CEO Bruce Steel will present on January 11, 2021, at 6:00 am EST.

What is the focus of Equillium's presentation at the conference?

The presentation will focus on itolizumab, a treatment for severe autoimmune and inflammatory disorders.

Where can I access the webcast of Equillium's presentation?

The webcast of the presentation will be available on Equillium's website under the 'Investors' section for 30 days.

What diseases does Equillium aim to treat with itolizumab?

Equillium is developing itolizumab for severe immuno-inflammatory diseases, including acute graft-versus-host disease, lupus, and uncontrolled asthma.